Benitec Biopharma Inc (BNTC)

In the past six months, Benitec Biopharma's stock price has been influenced by several events, including Q1 2026 earnings, positive interim clinical study results for BB-301, and FDA Fast Track designation for BB-301. Stock price movements have been varied, with shares falling due to profit-taking and S-3 registration statement filings, but also surging in response to positive momentum and renewed optimism around the gene therapy pipeline. Analyst sentiment has remained constructive, with a consensus "Moderate Buy" rating.

As a clinical-stage biotechnology company, Benitec Biopharma's products are currently in development and not yet commercialized. Therefore, there is no information available to indicate any demand seasonality for its products and services at this stage.

Benitec Biopharma, Inc. is a development-stage biotechnology company focused on advancing genetic medicines, operating within the Healthcare sector and Biotechnology industry. Their proprietary ddRNAi platform integrates RNA interference with gene therapy, aiming for sustained silencing of disease-causing genes after a single therapeutic administration. The company develops ddRNAi-based therapeutics for chronic and life-threatening conditions like OPMD and Chronic Hepatitis B, with its lead clinical program, BB-301, targeting OPMD-related dysphagia.

Benitec Biopharma Inc. is headquartered in Hayward, California, United States. The provided information does not detail a broader global geographic footprint for its operations or market reach beyond its US headquarters, as it is a clinical-stage company.

Benitec Biopharma's brand reputation appears positive within the investment community. Analysts maintain a strong "Moderate Buy" consensus rating for the stock, driven by the potential of its gene therapy technologies and the anticipated clinical progress of BB-301. Positive interim clinical trial data for BB-301 and the receipt of FDA Fast Track designation have positively impacted the company's reputation.

Benitec Biopharma Inc. has significant institutional ownership, with 111 institutional owners and shareholders holding a total of 25,039,259 shares, representing approximately 52.19% of the stock. Major institutional owners include Suvretta Capital Management, Llc, Janus Henderson Group Plc, Franklin Resources Inc, Adage Capital Partners Gp, L.l.c., Vanguard Group Inc, BlackRock, Inc., Nantahala Capital Management, LLC, and Infinitum Asset Management, Llc.